Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simnotrelvir + ritonavir + rifampicin
- Development stage
- Unknown
- Lead developer
- Jiangsu Simsheng Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SIM0417 + ritonavir + rifampicin is a drug combination used in clinical pharmacology studies to evaluate drug-drug interactions (DDI). It consists of **simnotrelvir** (SIM0417), an oral small-molecule antiviral that targets the SARS-CoV-2 3-chymotrypsin-like protease (3CLpro), which is essential for viral replication; **ritonavir**, a pharmacokinetic booster that inhibits the CYP3A4 enzyme to increase the plasma exposure of simnotrelvir; and **rifampicin**, a potent CYP3A4 inducer used as a clinical probe to assess the impact of metabolic induction on the pharmacokinetics of the simnotrelvir/ritonavir regimen. Simnotrelvir was developed by Simcere Pharmaceutical in collaboration with the Shanghai Institute of Materia Medica and the Wuhan Institute of Virology. The co-packaged product of simnotrelvir and ritonavir is marketed as Xiannuoxin for the treatment of mild-to-moderate COVID-19.
- Brand names
- XIANNUOXIN
- Other names
- SIM0417 + ritonavir + rifampicin
02
Targets
PXR (Pregnane X receptor)CYP3A4 (Cytochrome P450 3A4)ABCB1 (P-glycoprotein)Mpro (3C-like proteinase of SARS-CoV-2)PR (Progesterone receptor)
Beyond the preview
Go deeper on simnotrelvir + ritonavir + rifampicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simnotrelvir + ritonavir + rifampicin.